Welcome to our dedicated page for Small Pharma news (Ticker: DMTTF), a resource for investors and traders seeking the latest updates and insights on Small Pharma stock.
Small Pharma Inc. (DMTTF) is a pharmaceutical company focused on developing novel treatments for mental health disorders. With a strong emphasis on research and innovation, Small Pharma aims to revolutionize the treatment landscape for conditions like depression, PTSD, and anxiety.
The company's cutting-edge pipeline includes proprietary compounds that have shown promising results in preclinical studies. Small Pharma's approach prioritizes patient-centered care and strives to address the unmet needs of individuals suffering from mental health issues.
Small Pharma has established strategic partnerships with leading research institutions and experts in the field of psychiatry, ensuring a comprehensive and rigorous approach to drug development. The company's dedication to scientific excellence and patient well-being sets it apart in the competitive pharmaceutical industry.
Rhea-AI Summary
Cybin completes acquisition of Small Pharma, creating the largest deuterated DMT program and intellectual property portfolio in the psychedelic drug development sector. Two advanced clinical programs for depression and anxiety disorders. Phase 2 safety and efficacy data expected in late 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Summary
Small Pharma shareholders vote in favor of Cybin's acquisition, creating an international clinical-stage leader in psychedelic-based therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
-
Rhea-AI Summary
Small Pharma and Cybin announce final court approval for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
Rhea-AI Summary
Shareholders approve Cybin's acquisition of Small Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
-
Rhea-AI Summary
Small Pharma Inc. announces positive safety, tolerability, and efficacy data from its Phase Ib study on the interaction between SSRIs and SPL026 (DMT) in MDD patients. 100% of patients in the SSRI cohort responded to SPL026 with 92% in remission from depression. No differences in safety and tolerability between SSRI and non-SSRI cohorts. The potentially enhanced efficacy effect of a DMT-based treatment when administered with SSRIs could lead to greater therapeutic benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary
Cybin Inc. and Small Pharma Inc. have entered into a definitive arrangement agreement for Cybin to acquire all of Small Pharma's issued and outstanding securities in an all-share transaction. The exchange ratio implies consideration of approximately $0.10 per Small Pharma Share, representing a 43.6% premium. The combined entity will create an international clinical-stage leader in novel psychedelic therapeutics with the largest intellectual property portfolio in the sector. The transaction is expected to close in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
Rhea-AI Summary
Cybin to acquire Small Pharma in all-share transaction, creating a leader in psychedelic therapeutics. Small Pharma shareholders to receive 0.2409 Cybin Shares for each Small Pharma Share held, representing a 43.64% premium. Combined company will have the largest IP portfolio in the psychedelic drug development sector with 28 granted patents and 158 pending patents. Cybin expects to report Phase 2 safety and efficacy data for CYB003 in late 2023. Transaction expected to close in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Small Pharma Inc. has published its financial results for Q1 2023. Cash on hand is $13.2 million. The company completed dosing in its Phase Ib drug interaction study for SPL026 and expects results in Q3 2023. Results from the IM SPL026 Phase I study showed a mean psychedelic experience duration of approximately 45 minutes. SPL028 is currently dosing in a Phase I study with preliminary findings expected in Q4 2023. The company's IP portfolio has made significant progress with 26 patents granted and 95 patent applications pending.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.29%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.29%
Tags
FAQ
What is the market cap of Small Pharma (DMTTF)?
The market cap of Small Pharma (DMTTF) is approximately 37.5M.
What is Small Pharma Inc. focused on?
Small Pharma Inc. is focused on developing novel treatments for mental health disorders such as depression, PTSD, and anxiety.
What sets Small Pharma apart in the pharmaceutical industry?
Small Pharma is distinguished by its patient-centered approach, strategic partnerships with research institutions, and dedication to scientific excellence.
What is Small Pharma's pipeline like?
Small Pharma's pipeline includes proprietary compounds that have shown promising results in preclinical studies, offering hope for individuals with unmet mental health needs.
Who does Small Pharma collaborate with?
Small Pharma collaborates with leading research institutions and experts in psychiatry to ensure a comprehensive and rigorous approach to drug development.
What conditions does Small Pharma target?
Small Pharma targets mental health conditions such as depression, PTSD, and anxiety, aiming to revolutionize the treatment landscape for these disorders.
How does Small Pharma prioritize patient well-being?
Small Pharma prioritizes patient well-being by emphasizing patient-centered care in its drug development approach.
What results has Small Pharma achieved in preclinical studies?
Small Pharma's proprietary compounds have shown promising results in preclinical studies, demonstrating the potential for significant therapeutic benefits.
What is Small Pharma's mission?
Small Pharma's mission is to address the unmet needs of individuals suffering from mental health disorders by developing innovative and effective treatments.
Where can I find the latest news about Small Pharma Inc.?
Stay informed about the latest news and developments from Small Pharma Inc. by visiting their official website or following them on social media platforms.
How does Small Pharma contribute to the pharmaceutical industry?
Small Pharma contributes to the pharmaceutical industry by introducing novel approaches to mental health treatment and advancing scientific knowledge in the field of psychiatry.
Small Pharma Inc.